---
title: "Graft-Versus-Host Disease"
canonical: "https://www.pharmalegacy.com/indications/inflammation-immunity-autoimmunity/graft-versus-host-disease/"
lastmod: "2026-07-02T22:12:47+00:00"
generator: "llm-mirrors/1.0.19"
---

Studies show that acute Graft-versus-Host Disease (aGvHD) can occur in up to 50% of patients that are recipients of stem cell transplantation (HCT) from an HLA-matched sibling. This number goes even higher in unmatched donors. The incidence of chronic Graft-versus-Host Disease (cGvHD) ranges somewhere between 6% to 80%. More than 10% of patients suffering from GvHD will not survive its complications.
Hematopoietic stem cell transplantations (HSCTs) have been shown to be the cure to numerous blood and bone marrow cancers. The catch? GvHD is one of the most common complications in HSCTs. At PharmaLegacy, our end-goal is not the choice of a proper study model, or the meticulous compilation of data. Our end-goal is the same as yours: serving patients in need of better treatments.